ZACHARY DAMPIER: Open Payments
NPI 1780362756 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,128 in 104 payments from 13 companies in 2025. Trend: 2023 $26 · 2024 $641 · 2025 $2,128
Food & beverage: $2,128
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $386 |
| Teva Pharmaceuticals USA, Inc. | 15 | $381 |
| E.R. Squibb & Sons, L.L.C. | 16 | $324 |
| ABBVIE INC. | 30 | $290 |
| Neurocrine BioSciences, Inc. | 4 | $177 |
| Janssen Pharmaceuticals, Inc | 7 | $169 |
| Axsome Therapeutics, Inc. | 5 | $162 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| Alkermes, Inc. | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
Products named: REXULTI, COBENFY, VRAYLAR, UZEDY, INGREZZA, AUSTEDO XR, Auvelity, SPRAVATO.
Industry payments across MO — which companies pay providers there.
